Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus

Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty...

Ausführliche Beschreibung